AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2026)
AbCellera Biologics (ABCL) reported Income from Continuing Operations of 43165000.0 for Q1 2026, up 5.38% on a YoY basis from 40959928.14 in Q1 2025, and down 382.56% quarter-over-quarter from 8945000.0 in Q4 2025.
AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
AbCellera Biologics has reported Income from Continuing Operations for 7 years, with the latest figure at 43165000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 5.38% year-over-year to 43165000.0; the trailing twelve-month figure through Mar 2026 stood at 143956000.0 (up 14.24% YoY), and the FY2025 full-year result was 146412000.0, up 10.1% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 43165000.0, down from 8945000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 168573000.0 in Q1 2022, with the low at 57119000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 20018411.76 across 5 years, with a median of 34727000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 224.53% — and 2023, when it tumbled 349.93%.
- AbCellera Biologics' Income from Continuing Operations stood at 29893000.0 in 2022, then sank by 57.73% to 47150000.0 in 2023, then rose by 27.44% to 34210000.0 in 2024, then surged by 73.85% to 8945000.0 in 2025, then tumbled by 382.56% to 43165000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 43165000.0 (Q1 2026), 8945000.0 (Q4 2025), and 57119000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | AbCellera Biologics | 1.61 Bn | 1.51 Bn | - | -43.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.17 Mn |
| Dec 31, 2025 | -8.95 Mn |
| Sep 30, 2025 | -57.12 Mn |
| Jun 30, 2025 | -34.73 Mn |
| Mar 31, 2025 | -45.62 Mn |
| Dec 31, 2024 | -34.21 Mn |
| Sep 30, 2024 | -51.11 Mn |
| Jun 30, 2024 | -36.93 Mn |
| Mar 31, 2024 | -40.61 Mn |
| Dec 31, 2023 | -47.15 Mn |
| Sep 30, 2023 | -28.61 Mn |
| Jun 30, 2023 | -30.53 Mn |
| Mar 31, 2023 | -40.11 Mn |
| Dec 31, 2022 | -29.89 Mn |
| Sep 30, 2022 | 26.62 Mn |
| Jun 30, 2022 | -6.79 Mn |
| Mar 31, 2022 | 168.57 Mn |
| Dec 31, 2021 | 59.95 Mn |
| Sep 30, 2021 | -21.38 Mn |
| Jun 30, 2021 | -2.32 Mn |